Study of Durvalumab with Chemoradiotherapy for Women with Locally Advanced Cervical Cancer (CALLA) - CALLA

Study identifier:D9100C00001

ClinicalTrials.gov identifier:NCT03830866

EudraCT identifier:2018-002872-42

CTIS identifier:N/A

Study Complete

Official Title

A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer

Medical condition

Locally Advanced Cervical Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Cisplatin, Carboplatin

Sex

Female

Actual Enrollment

770

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 15 Feb 2019
Primary Completion Date: 20 Jan 2022
Study Completion Date: 03 Jul 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria